SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lawrence S Gaines, James C Slaughter, Sara N Horst, David A Schwartz, Dawn B Beaulieu, Kirsten L Haman, Li Wang, Christopher F Martin, Millie D Long, Robert S Sandler, Michael D Kappelman, Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn’s Disease, The American Journal of Gastroenterology, 2016,

    CrossRef

  2. 2
    Sofie Coenen, Ellen Weyts, Vera Ballet, Maja Noman, Gert Van Assche, Séverine Vermeire, Jan Van Emelen, Marc Ferrante, Identifying predictors of low adherence in patients with inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, 2016, 28, 5, 503

    CrossRef

  3. 3
    Michelle V. Prosberg, Marianne K. Vester-Andersen, Mikael Andersson, Tine Jess, Jon T. Andersen, Ida Vind, Flemming Bendtsen, Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis, Inflammatory Bowel Diseases, 2016, 22, 4, 925

    CrossRef

  4. 4
    Salam F. Zakko, Glenn L. Gordon, Uma Murthy, Shahriar Sedghi, Ronald Pruitt, Andrew C. Barrett, Enoch Bortey, Craig Paterson, William P. Forbes, Gary R. Lichtenstein, Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors, Postgraduate Medicine, 2016, 128, 3, 273

    CrossRef

  5. 5
    Sung Bum Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Soo Kim, Kwang Bum Cho, Kyung Sik Park, Min Kyu Chung, Seong Woo Jeon, Patients' beliefs and attitudes about their treatment for inflammatory bowel disease in Korea, Journal of Gastroenterology and Hepatology, 2016, 31, 3
  6. 6
    Eleni Vangeli, Savita Bakhshi, Anna Baker, Abigail Fisher, Delaney Bucknor, Ulrich Mrowietz, Andrew J. K. Östör, Laurent Peyrin-Biroulet, Ana P. Lacerda, John Weinman, A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases, Advances in Therapy, 2015, 32, 11, 983

    CrossRef

  7. 7
    Patricia Ruiz-Cuesta, Carlos González-Alayón, Juan Jurado-García, Eva M. Iglesias-Flores, José L. Barranco-Quintana, Luisa García-García, Isabel M. Salgueiro-Rodríguez, José M. Benitez-Cantero, Valle García-Sánchez, Adherence to a predefined vaccination program in patients with inflammatory bowel disease, Gastroenterología y Hepatología, 2015,

    CrossRef

  8. 8
    Xiaoang Wan, Andy T. Woods, Alejandro Salgado-Montejo, Carlos Velasco, Charles Spence, Assessing the expectations associated with pharmaceutical pill colour and shape, Food Quality and Preference, 2015, 45, 171

    CrossRef

  9. 9
    Anilga Tabibian, James H. Tabibian, Linda J. Beckman, Laura L. Raffals, Konstantinos A. Papadakis, Sunanda V. Kane, Predictors of Health-Related Quality of Life and Adherence in Crohn’s Disease and Ulcerative Colitis: Implications for Clinical Management, Digestive Diseases and Sciences, 2015, 60, 5, 1366

    CrossRef

  10. 10
    Mark P. Connolly, Johan P. Kuyvenhoven, Maarten J. Postma, Sandy K. Nielsen, Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing, Journal of Crohn's and Colitis, 2014, 8, 5, 357

    CrossRef

  11. 11
    Réme Mountifield, Jane M. Andrews, Antonina Mikocka-Walus, Peter Bampton, Covert dose reduction is a distinct type of medication non-adherence observed across all care settings in Inflammatory Bowel Disease, Journal of Crohn's and Colitis, 2014, 8, 12, 1723

    CrossRef

  12. 12
    Natalia Pedersen, Peter Thielsen, Lars Martinsen, Mette Bennedsen, Anne Haaber, Ebbe Langholz, Zsuzsanna Végh, Dana Duricova, Tine Jess, Sally Bell, Johan Burisch, Pia Munkholm, eHealth, Inflammatory Bowel Diseases, 2014, 20, 12, 2276

    CrossRef

  13. 13
    David Gillespie, Kerenza Hood, Daniel Farewell, Rachel Stenson, Christopher Probert, A. Barney Hawthorne, Electronic Monitoring of Medication Adherence in a 1-year Clinical Study of 2 Dosing Regimens of Mesalazine for Adults in Remission with Ulcerative Colitis, Inflammatory Bowel Diseases, 2014, 20, 1, 82

    CrossRef

  14. 14
    Gary R. Lichtenstein, Andrew C. Barrett, Enoch Bortey, Craig Paterson, William P. Forbes, Long-term Safety and Tolerability of Once-daily Mesalamine Granules in the Maintenance of Remission of Ulcerative Colitis, Inflammatory Bowel Diseases, 2014, 20, 8, 1399

    CrossRef

  15. 15
    Filippo Mocciaro, Roberto Di Mitri, Giuseppina Russo, Salvo Leone, Valerio Quercia, Motivational interviewing in inflammatory bowel disease patients: A useful tool for outpatient counselling, Digestive and Liver Disease, 2014, 46, 10, 893

    CrossRef

  16. 16
    Akbar K. Waljee, Ryan W. Stidham, Peter D.R. Higgins, Sandeep Vijan, Sameer D. Saini, Point–counterpoint: Are we overtreating patients with mild ulcerative colitis?, Journal of Crohn's and Colitis, 2014, 8, 1, 80

    CrossRef

  17. 17
    Christian P. Selinger, Yu Kinjo, D. Brian Jones, Peter Katelaris, Grace Chapman, Charles McDonald, Simon Lal, John McLaughlin, Andrew Robinson, Rupert W.L. Leong, Conveying medication benefits to ulcerative colitis patients and effects on patient attitudes regarding thresholds for adherence, Journal of Crohn's and Colitis, 2013, 7, 8, e312

    CrossRef

  18. You have free access to this content18
    J. R. Goodhand, N. Kamperidis, B. Sirwan, L. Macken, N. Tshuma, Y. Koodun, F. A. Chowdhury, N. M. Croft, N. Direkze, L. Langmead, P. M. Irving, D. S. Rampton, J. O. Lindsay, Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2013, 38, 9
  19. You have free access to this content19
    A. Robinson, M. Hankins, G. Wiseman, M. Jones, Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse, Alimentary Pharmacology & Therapeutics, 2013, 38, 5
  20. 20
    Annemiek J. Linn, Liset van Dijk, Edith G. Smit, Jesse Jansen, Julia C.M. van Weert, May you never forget what is worth remembering: The relation between recall of medical information and medication adherence in patients with inflammatory bowel disease, Journal of Crohn's and Colitis, 2013, 7, 11, e543

    CrossRef

  21. 21
    Stefan Schreiber, Julián Panés, Edouard Louis, Derek Holley, Mandy Buch, Kristine Paridaens, National differences in ulcerative colitis experience and management among patients from five European countries and Canada: An online survey, Journal of Crohn's and Colitis, 2013, 7, 6, 497

    CrossRef

  22. 22
    Rachel N. Greenley, Jennifer H. Kunz, Jennifer Walter, Kevin A. Hommel, Practical Strategies for Enhancing Adherence to Treatment Regimen in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, 2013, 19, 7, 1534

    CrossRef

  23. You have free access to this content23
    B. Flourié, H. Hagège, G. Tucat, D. Maetz, X. Hébuterne, J. P. Kuyvenhoven, T. G. Tan, M. J. Pierik, A. A. M. Masclee, O. Dewit, C. S. Probert, D. Aoucheta, Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis, Alimentary Pharmacology & Therapeutics, 2013, 37, 8
  24. 24
    Sharon Jedel, Patricia Merriman, Arthur Hoffman, Barbara Swanson, Louis F. Fogg, Ali Keshavarzian, Relationship of Mindfulness, Quality of Life, and Psychiatric Symptoms Among Patients with Ulcerative Colitis, Mindfulness, 2013, 4, 4, 296

    CrossRef

  25. 25
    Kevin A. Hommel, Rachel N. Greenley, Michele Herzer Maddux, Wendy N. Gray, Laura M. Mackner, Self-Management in Pediatric Inflammatory Bowel Disease, Journal of Pediatric Gastroenterology and Nutrition, 2013, 57, 2, 250

    CrossRef

  26. 26
    Ying Zhu, Ren-kuan Tang, Peng Zhao, Shi-sheng Zhu, Yong-guo Li, Jian-bo Li, Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials, European Journal of Gastroenterology & Hepatology, 2012, 24, 5, 487

    CrossRef

  27. You have free access to this content27
    N. Khan, A. M. Abbas, L. A. Bazzano, Y. N. Koleva, M. Krousel-Wood, Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system, Alimentary Pharmacology & Therapeutics, 2012, 36, 8
  28. 28
    Sara N Horst, Sunanda Kane, Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis, Expert Opinion on Pharmacotherapy, 2012, 13, 15, 2225

    CrossRef

  29. You have free access to this content29
    Brian G. Feagan, John K. MacDonald, Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis, Inflammatory Bowel Diseases, 2012, 18, 9
  30. 30
    A. Barney Hawthorne, Rachel Stenson, David Gillespie, Edwin T. Swarbrick, Anjan Dhar, Kapil C. Kapur, Kerry Hood, Chris S.J. Probert, One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis, Inflammatory Bowel Diseases, 2012, 18, 10
  31. 31
    Laurie Keefer, Bethany Doerfler, Caroline Artz, Optimizing management of Crohn's disease within a project management framework: Results of a pilot study, Inflammatory Bowel Diseases, 2012, 18, 2
  32. 32
    Stefan Schreiber, Julián Panés, Edouard Louis, Derek Holley, Mandy Buch, Kristine Paridaens, Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey, BMC Gastroenterology, 2012, 12, 1, 108

    CrossRef

  33. You have free access to this content33
    Gianmichele Meucci, Renato Fasoli, Simone Saibeni, Daniela Valpiani, Renzo Gullotta, Enrico Colombo, Renata D'Incà, Maddalena Terpin, Giovanni Lombardi, Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study, Inflammatory Bowel Diseases, 2012, 18, 6
  34. 34
    Sunanda Kane, Seymour Katz, M. Mazen Jamal, Michael Safdi, Ben Dolin, Dory Solomon, Mary Palmen, Karen Barrett, Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis, Inflammatory Bowel Diseases, 2012, 18, 6
  35. 35
    Hans Herfarth, The Role of Chemoprevention of Colorectal Cancer with 5-Aminosalicylates in Ulcerative Colitis, Digestive Diseases, 2012, 30, s2, 55

    CrossRef

  36. 36
    Sharon Dudley-Brown, Kathy Baker, Ulcerative Colitis From Patientsʼ Viewpoint, Gastroenterology Nursing, 2012, 35, 1, 54

    CrossRef

  37. 37
    Sunanda Kane, Brenda Becker, W. Scott Harmsen, Ashok Kurian, Donald E Morisky, Alan R Zinsmeister, Use of a Screening Tool to Determine Nonadherent Behavior in Inflammatory Bowel Disease, The American Journal of Gastroenterology, 2012, 107, 2, 154

    CrossRef

  38. 38
    Vincent Billioud, David Laharie, Jérôme Filippi, Xavier Roblin, Abderrahim Oussalah, Jean-Baptiste Chevaux, Xavier Hébuterne, Marc-André Bigard, Laurent Peyrin-Biroulet, Adherence to adalimumab therapy in Crohn's disease: A French multicenter experience, Inflammatory Bowel Diseases, 2011, 17, 1
  39. 39
    Christian P Selinger, Andrew Robinson, Rupert W Leong, Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease, Expert Opinion on Drug Safety, 2011, 10, 6, 863

    CrossRef

  40. 40
    Antonio Tursi, Raymond E. Joseph, Paul Streck, Expanding Applications: The Potential Usage of 5-Aminosalicylic Acid in Diverticular Disease, Digestive Diseases and Sciences, 2011, 56, 11, 3112

    CrossRef

  41. 41
    Tetyana Moshkovska, Margaret A. Stone, Roger M. Smith, John Bankart, Richard Baker, John F. Mayberry, Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: Results from an exploratory randomized controlled trial, Inflammatory Bowel Diseases, 2011, 17, 9
  42. 42
    M. Baudrant-Boga, B. Allenet, Inertie thérapeutique : et le patient dans tout ça ?, Médecine des Maladies Métaboliques, 2011, 5, S76

    CrossRef

  43. 43
    L. Leifeld, R. Pfützer, J. Morgenstern, P. R. Gibson, Y. Marakhouski, R. Greinwald, R. Mueller, W. Kruis, Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis, Alimentary Pharmacology & Therapeutics, 2011, 34, 9
  44. 44
    Tereza Bautzová, Miloslava Rabišková, Alf Lamprecht, Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease, Drug Development and Industrial Pharmacy, 2011, 37, 9, 1100

    CrossRef

  45. 45
    Alexander C Ford, Khurram J Khan, William J Sandborn, Sunanda V Kane, Paul Moayyedi, Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, 2011, 106, 12, 2070

    CrossRef

  46. 46
    W. Kruis, L. Jonaitis, J. Pokrotnieks, T. L. Mikhailova, M. Horynski, M. Bátovský, Y. S. Lozynsky, Y. Zakharash, I. Rácz, K. Kull, A. Vcev, M. Faszczyk, K. Dilger, R. Greinwald, R. Mueller, Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis, Alimentary Pharmacology & Therapeutics, 2011, 33, 3
  47. 47
    Laurie Keefer, Jennifer L. Kiebles, Tiffany H. Taft, The role of self-efficacy in inflammatory bowel disease management: Preliminary validation of a disease-specific measure, Inflammatory Bowel Diseases, 2011, 17, 2
  48. 48
    Sunanda V. Kane, Michael Sumner, Dory Solomon, Matthew Jenkins, Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database, Digestive Diseases and Sciences, 2011, 56, 12, 3463

    CrossRef

  49. 49
    J.P. Gisbert, F. Gomollón, J. Hinojosa, A. López San Román, Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain, Journal of Crohn's and Colitis, 2010, 4, 5, 567

    CrossRef

  50. 50
    Peter Laszlo Lakatos, Zsofia Czegledi, Gyula David, Zsofia Kispal, Lajos S Kiss, Karoly Palatka, Tunde Kristof, Ferenc Nagy, Agnes Salamon, Pal Demeter, Pal Miheller, Tamas Szamosi, Janos Banai, Maria Papp, Laszlo Bene, Agota Kovacs, Istvan Racz, Laszlo Lakatos, Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease, Journal of Crohn's and Colitis, 2010, 4, 3, 283

    CrossRef

  51. 51
    Pia Munkholm, Pierre Michetti, Chris S. Probert, Margarita Elkjaer, Philippe Marteau, Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine, European Journal of Gastroenterology & Hepatology, 2010, 22, 8, 912

    CrossRef

  52. 52
    Melvin B. Heyman, Jaroslaw Kierkus, Jean Spénard, Hadia Shbaklo, Monique Giguere, Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents, Inflammatory Bowel Diseases, 2010, 16, 11
  53. 53
    C A Jackson, J Clatworthy, A Robinson, Rob Horne, Factors Associated With Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review, The American Journal of Gastroenterology, 2010, 105, 3, 525

    CrossRef

  54. 54
    Fernando Bermejo, Antonio López-San Román, Alicia Algaba, Iván Guerra, Paz Valer, Silvia García-Garzón, Belén Piqueras, Carlos Villa, Andrea Bermejo, José L. Rodríguez-Agulló, Factors that modify therapy adherence in patients with inflammatory bowel disease, Journal of Crohn's and Colitis, 2010, 4, 4, 422

    CrossRef

  55. 55
    Alan C. Moss, Nabeel Chaudhary, Melissa Tukey, Jahvari Junior, Didia Cury, Kenneth R. Falchuk, Adam S. Cheifetz, Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis — A prospective study, Journal of Crohn's and Colitis, 2010, 4, 2, 171

    CrossRef

  56. 56
    S. V. Kane, A. Robinson, Review article: understanding adherence to medication in ulcerative colitis – innovative thinking and evolving concepts, Alimentary Pharmacology & Therapeutics, 2010, 32, 9
  57. 57
    Paul F. Cook, Suzie Emiliozzi, Dana El-Hajj, Mishcha M. McCabe, Telephone nurse counseling for medication adherence in ulcerative colitis: A preliminary study, Patient Education and Counseling, 2010, 81, 2, 182

    CrossRef

  58. 58
    László Lakatos, Zsófia Czeglédi, Gyula Dávid, Zsófi Kispál, Lajos S. Kiss, Károly Palatka, Tünde Kristóf, Tamás Molnár, Ágnes Salamon, Pál Demeter, Pál Miheller, Tamás Szamosi, János Banai, Mária Papp, László Bene, Ágota Kovács, István Rácz, Péter László Lakatos, Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease, Orvosi Hetilap, 2010, 151, 7, 250

    CrossRef

  59. 59
    Fernando Bermejo San José, Antonio López San Román, Alicia Algaba García, Adhesión al tratamiento en la enfermedad inflamatoria intestinal: estrategias para mejorarla, Gastroenterología y Hepatología, 2009, 32, 31

    CrossRef

  60. 60
    T. MOSHKOVSKA, M. A. STONE, J. CLATWORTHY, R. M. SMITH, J. BANKART, R. BAKER, J. WANG, R. HORNE, J. F. MAYBERRY, An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements, Alimentary Pharmacology & Therapeutics, 2009, 30, 11-12
  61. 61
    C. PRANTERA, A. KOHN, M. CAMPIERI, R. CAPRILLI, M. COTTONE, F. PALLONE, V. SAVARINO, G. C. STURNIOLO, M. VECCHI, A. ARDIA, S. BELLINVIA, Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®, Alimentary Pharmacology & Therapeutics, 2009, 30, 9
  62. 62
    Lesley A. Graff, John R. Walker, Charles N. Bernstein, Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management, Inflammatory Bowel Diseases, 2009, 15, 7
  63. 63
    J. E. BAARS, Z. ZELINKOVA, P. B. F. MENSINK, T. MARKUS, C. W. N. LOOMAN, E. J. KUIPERS, C. J. VAN DER WOUDE, High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study, Alimentary Pharmacology & Therapeutics, 2009, 30, 8
  64. 64
    David T. Rubin, Corey A. Siegel, Sunanda V. Kane, David G. Binion, Remo Panaccione, Marla C. Dubinsky, Edward V. Loftus, Joseph Hopper, Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey, Inflammatory Bowel Diseases, 2009, 15, 4
  65. 65
    Axel U. Dignass, Bernd Bokemeyer, Henning Adamek, Michael Mross, Lars Vinter-Jensen, Norbert Börner, Jouni Silvennoinen, Gie Tan, Marco Oudkerk Pool, Theo Stijnen, Peter Dietel, Tobias Klugmann, Severine Vermeire, Aomesh Bhatt, Henri Veerman, Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis, Clinical Gastroenterology and Hepatology, 2009, 7, 7, 762

    CrossRef

  66. 66
    Rob Horne, Rhian Parham, Richard Driscoll, Andrew Robinson, Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease, Inflammatory Bowel Diseases, 2009, 15, 6
  67. You have free access to this content67
    S. V. KANE, N. A. ACCORTT, S. MAGOWAN, D. BRIXNER, Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis, Alimentary Pharmacology & Therapeutics, 2009, 29, 8
  68. 68
    Ellen J Scherl, Ronald Pruitt, Glenn L Gordon, Mark Lamet, Audrey Shaw, Shirley Huang, Shadreck Mareya, William P Forbes, Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, The American Journal of Gastroenterology, 2009, 104, 6, 1452

    CrossRef

  69. 69
    P. D. R. HIGGINS, D. T. RUBIN, K. KAULBACK, P. S. SCHOENFIELD, S. V. KANE, Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares, Alimentary Pharmacology & Therapeutics, 2009, 29, 3
  70. You have free access to this content70
    J. R. GRAY, E. LEUNG, J. SCALES, Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapy, Alimentary Pharmacology & Therapeutics, 2009, 29, 10
  71. 71
    Zunwu Zhang, Hugh Kennedy, Ulcerative colitis: current medical therapy and strategies for improving medication adherence, European Journal of Gastroenterology & Hepatology, 2009, 21, 1, 1

    CrossRef

  72. 72
    Seema A Patil, Alan C Moss, Balsalazide disodium for the treatment of ulcerative colitis, Expert Review of Gastroenterology & Hepatology, 2008, 2, 2, 177

    CrossRef

  73. 73
    Nielsen Q Fernandez-Becker, Alan C Moss, Improving Delivery of Aminosalicylates in Ulcerative Colitis, Drugs, 2008, 68, 8, 1089

    CrossRef

  74. 74
    Stefan Schreiber, Michael A Kamm, Gary R Lichtenstein, Mesalamine with MMX™ technology for the treatment of ulcerative colitis, Expert Review of Gastroenterology & Hepatology, 2008, 2, 3, 299

    CrossRef

  75. 75
    Mary Y Hu, Mark A Peppercorn, MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis, Expert Opinion on Pharmacotherapy, 2008, 9, 6, 1049

    CrossRef

  76. 76
    Joanne Wilson, Novel 5-Aminosalicylic Acid Formulations in Ulcerative Colitis, Gastroenterology Nursing, 2008, 31, 4, 286

    CrossRef

  77. 77
    Tetyana Moshkovska, Margaret Stone, Richard Baker, John Mayberry, Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, Inflammatory Bowel Diseases, 2008, 14, 6
  78. 78
    E. Jan Irvine, Quality of life of patients with ulcerative colitis: Past, present, and future, Inflammatory Bowel Diseases, 2008, 14, 4
  79. 79
    A. ROBINSON, Review article: improving adherence to medication in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2008, 27,
  80. 80
    A. B. HAWTHORNE, G. RUBIN, S. GHOSH, Review article: medication non-adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies, Alimentary Pharmacology & Therapeutics, 2008, 27, 12
  81. 81
    N. WESTWOOD, S. P. L. TRAVIS, Review article: what do patients with inflammatory bowel disease want for their clinical management?, Alimentary Pharmacology & Therapeutics, 2008, 27,
  82. 82
    R. D’INCÀ, P. BERTOMORO, K. MAZZOCCO, M. G. VETTORATO, R. RUMIATI, G. C. STURNIOLO, Risk factors for non-adherence to medication in inflammatory bowel disease patients, Alimentary Pharmacology & Therapeutics, 2008, 27, 2
  83. 83
    Subrata Ghosh, The challenges of medication non-adherence in ulcerative colitis: Practical suggestions to help patients, Journal of Crohn's and Colitis, 2008, 2, 1, 97

    CrossRef

  84. 84
    B. BOKEMEYER, A. TEML, C. ROGGEL, P. HARTMANN, C. FISCHER, E. SCHAEFFELER, M. SCHWAB, Adherence to thiopurine treatment in out-patients with Crohn’s disease, Alimentary Pharmacology & Therapeutics, 2007, 26, 2
  85. 85
    Gary R. Lichtenstein, Michael A. Kamm, Prabhakar Boddu, Natalya Gubergrits, Andrew Lyne, Todd Butler, Kirstin Lees, Raymond E. Joseph, William J. Sandborn, Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis, Clinical Gastroenterology and Hepatology, 2007, 5, 1, 95

    CrossRef

  86. 86
    Gerassimos J. Mantzaris, Anastasios Roussos, Chryssostomos Kalantzis, Stavroula Koilakou, Nickolaos Raptis, Nickolaos Kalantzis, How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?, Inflammatory Bowel Diseases, 2007, 13, 4
  87. 87
    Sunanda Kane, Just a Spoonful of Sugar Helps the Medicine Go Down?If Only It Was That Simple! Nonadherence in Inflammatory Bowel Disease, The American Journal of Gastroenterology, 2007, 102, 7, 1427

    CrossRef

  88. 88
    Petr Cerveny, Martin Bortlik, Jirí Vlcek, Ales Kubena, Milan Lukás, Non-adherence to treatment in inflammatory bowel disease in Czech Republic, Journal of Crohn's and Colitis, 2007, 1, 2, 77

    CrossRef

  89. 89
    Petr Červený, Martin Bortlík, Aleš Kuběna, Jiří Vlček, Peter Laszlo Lakatos, Milan Lukáš, Nonadherence in inflammatory bowel disease: Results of factor analysis, Inflammatory Bowel Diseases, 2007, 13, 10
  90. 90
    Maria M Oliva-Hemker, Vivian Abadom, Carmen Cuffari, Richard E Thompson, Nonadherence With Thiopurine Immunomodulator and Mesalamine Medications in Children with Crohn Disease, Journal of Pediatric Gastroenterology and Nutrition, 2007, 44, 2, 180

    CrossRef

  91. 91
    Nabil Tahri, Observance thérapeutique et maladies inflammatoires chroniques de l'intestin, La Presse Médicale, 2007, 36, 9, 1236

    CrossRef

  92. 92
    Jason P. Ediger, John R. Walker, Lesley Graff, Lisa Lix, Ian Clara, Patricia Rawsthorne, Linda Rogala, Norine Miller, Cory McPhail, Kathleen Deering, Charles N. Bernstein, Predictors of Medication Adherence in Inflammatory Bowel Disease, The American Journal of Gastroenterology, 2007, 102, 7, 1417

    CrossRef

  93. 93
    Alan C Moss, Mark A Peppercorn, The risks and the benefits of mesalazine as a treatment for ulcerative colitis, Expert Opinion on Drug Safety, 2007, 6, 2, 99

    CrossRef

  94. 94
    Edward V. Loftus, A practical perspective on ulcerative colitis: Patients' needs from aminosalicylate therapies, Inflammatory Bowel Diseases, 2006, 12, 12
  95. 95
    Raymond K. Cross, Mohit Arora, Joseph Finkelstein, Acceptance of Telemanagement is High in Patients With Inflammatory Bowel Disease, Journal of Clinical Gastroenterology, 2006, 40, 3, 200

    CrossRef

  96. 96
    Isabel Bernal, Eugeni Domènech, Esther Garcia-Planella, Laura Marín, Míriam Mañosa, Mercè Navarro, Eduard Cabré, Miquel A. Gassull, Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease, Digestive Diseases and Sciences, 2006, 51, 12, 2165

    CrossRef

  97. 97
    G. D'HAENS, D. HOMMES, L. ENGELS, F. BAERT, L. VAN DER WAAIJ, P. CONNOR, J. RAMAGE, O. DEWIT, M. PALMEN, D. STEPHENSON, R. JOSEPH, Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study, Alimentary Pharmacology & Therapeutics, 2006, 24, 7
  98. 98
    Å. Nilsson, Optimizing management of distal ulcerative colitis, Scandinavian Journal of Gastroenterology, 2006, 41, 5, 511

    CrossRef

  99. 99
    R. D. COHEN, Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis, Alimentary Pharmacology & Therapeutics, 2006, 24, 3
  100. 100
    A. LÓPEZ-SANROMÁN, F. BERMEJO, Review article: how to control and improve adherence to therapy in inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2006, 24,
  101. 101
    P. DESREUMAUX, S. GHOSH, Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence, Alimentary Pharmacology & Therapeutics, 2006, 24,
  102. 102
    S. V. KANE, Systematic review: adherence issues in the treatment of ulcerative colitis, Alimentary Pharmacology & Therapeutics, 2006, 23, 5
  103. 103
    R. BERGMAN, M. PARKES, Systematic review: the use of mesalazine in inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2006, 23, 7
  104. 104
    E.G. Giannini, S.V. Kane, R. Testa, V. Savarino, 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: Can we afford to wait for ‘best evidence’?, Digestive and Liver Disease, 2005, 37, 10, 723

    CrossRef

  105. 105
    Steven Masson, David Nylander, John C Mansfield, How Important is Onset of Action in Ulcerative Colitis Therapy?, Drugs, 2005, 65, 15, 2069

    CrossRef

  106. 106
    Gary R. Lichtenstein, Stephen B. Hanauer, Sunanda V. Kane, Daniel H. Present, Crohn's is not a 6-week disease. Lifelong management of mild to moderate Crohn's disease, Inflammatory Bowel Diseases, 2004, 10, 8
  107. 107
    A. Robinson, Inflammatory bowel disease — empowering the patient and improving outcome, Alimentary Pharmacology & Therapeutics, 2004, 20,
  108. 108
    Stephen B Hanauer, Medical therapy for ulcerative colitis 2004, Gastroenterology, 2004, 126, 6, 1582

    CrossRef

  109. 109
    A. Raedler, C. Behrens, P. Bias, Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized-controlled trial, Alimentary Pharmacology & Therapeutics, 2004, 20, 11-12
  110. 110
    Laurie Keefer, Tiffany H. Taft, Jennifer L. Kiebles, Gastrointestinal Diseases, Handbook of Psychology, Second Edition,
  111. 111
    Christian P. Selinger, Andrew Robinson, Non-adherence to Medical Treatment,
  112. 112
    Brian G Feagan, John K MacDonald, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis, The Cochrane Library,
  113. 113
    Yongjun Wang, Claire E Parker, Tania Bhanji, Brian G Feagan, John K MacDonald, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis, The Cochrane Library,
  114. 114
    Brian G Feagan, John K MacDonald, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, The Cochrane Library,